knowledge -WSS

knowledge

author：explore 2025-09-28 01:39:05 - browse：68

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Why a market frenzy over new weight loss drugs defies logic

WSS

GSK Flovent asthma inhalers replaced by authorized generics

Is there really a nursing shortage in the U.S.?

Federal weight loss drug coverage is 30 years out of date

Study on Amgen’s bispecific immunotherapy produces positive data

Cassava Sciences’ Alzheimer’s clinical trials should be halted

CZI to create biohub to build anti

entertainment

knowledge

explore

Peter Hotez and the public health issue of online harassment

STAT Summit: Ending the crisis of Black deaths in the U.S.

Cancer drug shortages should be causing more outrage

New weight loss drugs work. But how can they best be used?

In Memoriam: Notable people who died in 2023

U.K. sequencing study surfaces new findings about tumor DNA

Tori Bowie and the unacceptable rates of Black maternal death

Videos point to link between seizures and unexplained toddler deaths

Medical records are filled with copy

Why a market frenzy over new weight loss drugs defies logic

entertainment

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

STAT Summit: Ending the crisis of Black deaths in the U.S.

Goldman Sachs launches $650M fund for life science investments

hotspot

focus

focus

entertainment